LLS clinical trials will use the FDA-cleared BioSticker to evaluate correlation of vital signs and select symptoms to treatment
BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company announced the company has entered into a strategic partnership with The Leukemia & Lymphoma Society (LLS) to incorporate use of the BioSticker™ medical wearable device and data services in clinical trials of hematological cancer patients.
The BioSticker is the first FDA-cleared single-use medical device that enables 30 days of continuous vital signs monitoring. The BioIntelliSense medical grade Data-as-a-Service (DaaS) platform and FDA 510(k) Class II medical wearable device provides a new standard for Remote Patient Monitoring (RPM), by combining an effortless patient experience with medical grade clinical accuracy, for cost-effective virtual trials.
The LLS clinical trials will include use of the BioSticker medical device for the continuous collection of vital sign and physiological data which includes temperature, heart rate, respiratory rate at rest, activity level and body position. The BioSticker data services and advanced analytics will be used by LLS to correlate symptoms to treatment.
“Our medical grade devices and data services can have a profound impact on oncology care by unlocking unique and actionable clinical intelligence to guide treatment decisions,” said James Mault, MD, CEO of BioIntelliSense. “It is a major focus of our company and we are extremely proud to be partnering with The Leukemia & Lymphoma Society as a global leader in blood cancer research and support services.”